Should You Pick Pfizer Stock At $30?
Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE stock has ample
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The company also faces potential sales declines in othe...
This High-Yield Dividend Stock Is a Proven Wealth Creator
In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has been among the group's worst performers this year.
UK regulator approves Pfizer's hair loss drug
Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease.
Pfizer Posted a Steep Loss. Is It Time to Sell?
Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in the third quarter.
Pfizer quarterly results hit by soft demand for COVID-19 products
Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reported on Tuesday.
We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Travis Kelce, acquiring BioHaven and more.
Pfizer CEO Albert Bourla talks Q3 earnings results with Jim Cramer
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Travis Kelce, acquiring BioHaven and more.
Pfizer to Sees No Major M&A Activity in 2024: CEO Bourla
Pfizer Chairman and CEO Albert Bourla says the company is still in the market for acquisitions following its $43 billion acquisition of cancer biotech firm Seagen Inc., but 2024 will not see any ma...
Pfizer reports first quarterly loss since 2019
Shares of Pfizer (PFE) slipped after the pharmaceutical company reported its first quarterly loss since 2019 in its third quarter earnings. Pfizer incurred a $5.5 billion non-cash write-off due to ...
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Pfizer Earnings Weighed Down Again by Dwindling COVID Sales
Unused stockpiles of COVID-19 treatment Paxlovid and muted demand for the same illness' vaccine weighed down on Pfizer's (PFE) third quarter earnings.
Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates
Pfizer (PFE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to earnings of $1.78 per share a year ago.
Pfizer Q3 earnings beat does little for the battered share price
A smaller-than-expected third-quarter loss from Pfizer Inc (NYSE:PFE) was not enough to move the stock pre-market as it revealed the scars from a tail-off in demand from Covid treatments. Disclosin...
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Related Companies